checkAd

     353  0 Kommentare Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

    Not intended for US, Canada or UK-based media

    Darmstadt, Germany (ots/PRNewswire) -

    - Eight high priority immuno-oncology clinical development studies
    ongoing or expected to commence in 2019, including studies in
    non-small cell lung and biliary tract cancers
    - Merck will receive an upfront payment of EUR300 million and is
    eligible for potential development milestone payments of up to
    EUR500 million triggered by data from the M7824 lung cancer
    program, plus future approval and commercial milestones of up to
    EUR2.9 billion for a total potential deal value of up to EUR3.7
    billion

    Merck, a leading science and technology company, and GSK, a
    science-led global healthcare company, today announced that the
    companies have entered into a global strategic alliance to jointly
    develop and commercialize M7824 (bintrafusp alfa*). M7824 is an
    investigational bifunctional fusion protein immunotherapy that is
    currently in clinical development, including potential registration
    studies, for multiple difficult-to-treat cancers. This includes a
    Phase II trial to investigate M7824 compared with pembrolizumab as a
    first-line treatment in patients with PD-L1 expressing advanced
    non-small cell lung cancer (NSCLC).

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Merck KGaA!
    Short
    174,81€
    Basispreis
    1,05
    Ask
    × 14,88
    Hebel
    Long
    153,62€
    Basispreis
    1,16
    Ask
    × 14,04
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    To view the Multimedia News Release, please click: https://www.m
    ultivu.com/players/uk/8491551-merck-and-gsk-announce-global-alliance/

    M7824 is designed to simultaneously target two immuno-suppressive
    pathways, transforming growth factor-? (TGF-?) trap and an
    anti-programmed cell death ligand-1 (PD-L1), that are commonly used
    by cancer cells to evade the immune system. Bifunctional antibodies
    aim to increase efficacy above and beyond that achieved with
    individual therapies or combinations of individual therapies.1 M7824
    has the potential to offer new ways to fight difficult-to-treat
    cancers beyond the established PD-1/PD-L1 class. In addition to use
    as a single agent, M7824 is also being considered for use in
    combination with other assets from the pipelines of both companies.

    "Our bifunctional fusion protein M7824 has the potential to bring
    new answers to patients living with cancer. Together with GSK we aim
    to drive a paradigm shift in the treatment of cancer as the leader in
    this novel class of immunotherapies," said Belén Garijo, Member of
    the Executive Board and CEO Healthcare of Merck. "GSK clearly emerged
    as the ideal partner due to their strong commitment to oncology, and
    the complementary talent and capabilities they will bring to our
    alliance. We now look forward to harnessing the full potential of
    Seite 1 von 3


    news aktuell
    0 Follower
    Autor folgen

    Verfasst von news aktuell
    Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers - Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million and is …

    Schreibe Deinen Kommentar

    Disclaimer